LGM Pharma, a provider of tailored API and CDMO services for the full drug product lifecycle, is investing over $6 million to expand its Rosenberg, Texas manufacturing facility as part of its Phase I CDMO growth strategy. The expansion will increase capacity for liquid, suspension, semi-solid, and suppository drug products, addressing the rising demand for reliable U.S.-based production.
The Rosenberg facility enhancements will accommodate increased production volumes while ensuring compliance with FDA regulations and current good manufacturing practices (cGMP). The site will remain fully operational throughout the expansion.
“LGM Pharma is making strategic investments to support the growing need for high-quality domestic drug manufacturing,” said Prasad Raje, Ph.D., CEO of LGM Pharma. “We have several prescription products in development, including both 505(b)(2) and ANDA projects, with one ANDA already submitted to the FDA. This expansion ensures we can continue providing our customers with the quality, reliability, and confidence they need to bring these products to market.”
LGM Pharma’s investment will strengthen both infrastructure and quality systems at the Rosenberg facility, enhancing its ability to manufacture prescription drug products, including topical and suppository products, while maintaining high regulatory and quality standards.
Furthermore, as supply chain disruptions, tariffs, and global uncertainties continue to impact pharmaceutical manufacturing, LGM Pharma’s investment provides a dependable domestic solution. The expansion also includes track and trace serialization capabilities at the Rosenberg facility, aligning with regulatory requirements to enhance product traceability and ensure compliance.
